Immunohistochemical analysis of the patients’ tumors (Figure 4) suggested that the repurposed drugs inhibited GSK3β activity in the tumor cells, decreased expression of MIB-1 cell proliferation marker, and reduced invasion by the residual tumor cells. The gene discussed is MIB1; the disease is neoplasm.